Second GSK Neuro Spin-Out Targets Hearing Loss, Attracts Up To £10m
SV Life Sciences and Imperial Innovations pledge up to £10 million for GSK spin-out Autifony, the second to emerge from unwanted neurosciences R&D.
SV Life Sciences and Imperial Innovations pledge up to £10 million for GSK spin-out Autifony, the second to emerge from unwanted neurosciences R&D.